Physician profile
Mark J Samson
NPI 1386637189
$3,079.27
in general payments reported to CMS, 2019-2025
33 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $331 · 2021: $466 · 2022: $347 · 2023: $280 · 2024: $341 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $474.94 | 2019-2025 | Veozah |
| Pfizer INC. | $316.43 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $290.44 | 2019-2021 | |
| Abbvie INC. | $269.73 | 2021-2025 | Vraylar |
| Amgen INC. | $215.82 | 2021-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $215.18 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $182.73 | 2019-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $161.15 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $149.25 | 2019-2022 | |
| Esperion Therapeutics, INC. | $96.00 | 2020 | |
| Philips North America LLC | $77.00 | 2023-2025 | Ecc Solutions |
| Seqirus USA INC | $65.04 | 2024-2025 | Fluad, Flucelvax |
| Zealand Pharma US, INC. | $63.34 | 2021-2022 | |
| Abbott Laboratories | $61.85 | 2023-2025 | Freestyle Libre |
| Supernus Pharmaceuticals, INC. | $43.16 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $42.33 | 2024-2025 | Rexulti |
| Medtronic, INC. | $31.35 | 2022-2024 | Kyphon Express II Kyphopak Tray |
| Sunovion Pharmaceuticals INC. | $31.27 | 2021 | |
| Biogen, INC. | $29.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $29.14 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.24 | 2024 | Ofev |
| Xeris Pharmaceuticals, INC. | $24.62 | 2022 | |
| Allergan, INC. | $23.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.98 | 2025 | Xifaxan |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.74 | 2023 | |
| Lilly USA, LLC | $17.26 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.76 | 2021 | |
| Dexcom, INC. | $15.33 | 2025 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $15.01 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.96 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $12.42 | 2022 | |
| Hikma Pharmaceuticals USA | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Samson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.